Figure 3.

Treatment-related transcriptomic changes in tumor and peripheral blood. A, Left: differential gene expression between tumors collected at pretherapy and at surgery was assessed in all patients with evaluable paired tumor samples (total, n = 13 patients). Paired samples in each arm had the following MPR rates: durvalumab monotherapy: 0/4; durvalumab + oleclumab: 1/5; durvalumab + monalizumab: 2/4. Right: gene set enrichment analysis (GSEA) was used to identify gene sets and signatures significantly down- or upregulated from pretherapy to surgery on each treatment arm. The durvalumab monotherapy arm is not pictured, as no significant gene enrichment was observed. B, Patients with MPR are indicated in closed teal circle; patients without MPR are indicated in open gray circle. Top and top middle: mRNA from select genes associated with T cells, NK cells, and cytotoxicity is shown from pretreatment and surgery tumor tissue (n = 69 samples; n = 35 pretherapy, n = 34 surgery). Patients with paired samples (an evaluable sample from both pretreatment and surgery) are connected by a line. Bottom and bottom middle: mRNA from select genes associated with tumor and blood lymphocyte recruitment is shown from pretherapy to end-of-treatment peripheral blood collections (n = 120 samples; n = 65 pretherapy, n = 55 end-of-treatment). Y-axes units are all [Log₂ (TPM + 0.01)], where TPM is transcripts per million. DN, down; Durva, durvalumab; IPA, Ingenuity Pathway Analysis; Mona, monalizumab; Ole, oleclumab.